300 related articles for article (PubMed ID: 29249276)
1. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
Thwaites GE; Scarborough M; Szubert A; Nsutebu E; Tilley R; Greig J; Wyllie SA; Wilson P; Auckland C; Cairns J; Ward D; Lal P; Guleri A; Jenkins N; Sutton J; Wiselka M; Armando GR; Graham C; Chadwick PR; Barlow G; Gordon NC; Young B; Meisner S; McWhinney P; Price DA; Harvey D; Nayar D; Jeyaratnam D; Planche T; Minton J; Hudson F; Hopkins S; Williams J; Török ME; Llewelyn MJ; Edgeworth JD; Walker AS;
Lancet; 2018 Feb; 391(10121):668-678. PubMed ID: 29249276
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.
Thwaites GE; Scarborough M; Szubert A; Saramago Goncalves P; Soares M; Bostock J; Nsutebu E; Tilley R; Cunningham R; Greig J; Wyllie SA; Wilson P; Auckland C; Cairns J; Ward D; Lal P; Guleri A; Jenkins N; Sutton J; Wiselka M; Armando GR; Graham C; Chadwick PR; Barlow G; Gordon NC; Young B; Meisner S; McWhinney P; Price DA; Harvey D; Nayar D; Jeyaratnam D; Planche T; Minton J; Hudson F; Hopkins S; Williams J; Török ME; Llewelyn MJ; Edgeworth JD; Walker AS
Health Technol Assess; 2018 Oct; 22(59):1-148. PubMed ID: 30382016
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.
Thwaites G; Auckland C; Barlow G; Cunningham R; Davies G; Edgeworth J; Greig J; Hopkins S; Jeyaratnam D; Jenkins N; Llewelyn M; Meisner S; Nsutebu E; Planche T; Read RC; Scarborough M; Soares M; Tilley R; Török ME; Williams J; Wilson P; Wyllie S; Walker AS;
Trials; 2012 Dec; 13():241. PubMed ID: 23249501
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
5. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
[TBL] [Abstract][Full Text] [Related]
6. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial.
Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC
Trials; 2018 May; 19(1):297. PubMed ID: 29843781
[TBL] [Abstract][Full Text] [Related]
8. Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: Observational analyses within the ARREST trial.
Szubert A; Bailey SL; Cooke GS; Peto T; Llewelyn MJ; Edgeworth JD; Walker AS; Thwaites GE;
J Infect; 2019 Oct; 79(4):332-340. PubMed ID: 31398375
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.
Kaasch AJ; López-Cortés LE; Rodríguez-Baño J; Cisneros JM; Dolores Navarro M; Fätkenheuer G; Jung N; Rieg S; Lepeule R; Coutte L; Bernard L; Lemaignen A; Kösters K; MacKenzie CR; Soriano A; Hagel S; Fantin B; Lafaurie M; Talarmin JP; Dinh A; Guimard T; Boutoille D; Welte T; Reuter S; Kluytmans J; Martin ML; Forestier E; Stocker H; Vitrat V; Tattevin P; Rommerskirchen A; Noret M; Adams A; Kern WV; Hellmich M; Seifert H;
Lancet Infect Dis; 2024 May; 24(5):523-534. PubMed ID: 38244557
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
Cross GB; Sari IP; Kityo C; Lu Q; Pokharkar Y; Moorakonda RB; Thi HN; Do Q; Dalay VB; Gutierrez E; Balanag VM; Castillo RJ; Mugerwa H; Fanusi F; Kwan P; Chew KL; Paton NI;
Lancet Infect Dis; 2023 Jul; 23(7):847-855. PubMed ID: 36966799
[TBL] [Abstract][Full Text] [Related]
11. Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus - a retrospective cohort study.
Forsblom E; Ruotsalainen E; Järvinen A
PLoS One; 2015; 10(4):e0122824. PubMed ID: 25874546
[TBL] [Abstract][Full Text] [Related]
12. High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial.
Ruslami R; Fregonese F; Apriani L; Barss L; Bedingfield N; Chiang V; Cook VJ; Fisher D; Flores E; Fox GJ; Johnston J; Lim RK; Long R; Paulsen C; Nguyen TA; Nhung NV; Gibson D; Valiquette C; Benedetti A; Menzies D
Lancet Respir Med; 2024 Jun; 12(6):433-443. PubMed ID: 38552659
[TBL] [Abstract][Full Text] [Related]
13. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients.
Ruotsalainen E; Järvinen A; Koivula I; Kauma H; Rintala E; Lumio J; Kotilainen P; Vaara M; Nikoskelainen J; Valtonen V;
J Intern Med; 2006 Feb; 259(2):179-90. PubMed ID: 16420547
[TBL] [Abstract][Full Text] [Related]
15. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Blum CA; Nigro N; Briel M; Schuetz P; Ullmer E; Suter-Widmer I; Winzeler B; Bingisser R; Elsaesser H; Drozdov D; Arici B; Urwyler SA; Refardt J; Tarr P; Wirz S; Thomann R; Baumgartner C; Duplain H; Burki D; Zimmerli W; Rodondi N; Mueller B; Christ-Crain M
Lancet; 2015 Apr; 385(9977):1511-8. PubMed ID: 25608756
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of GABA
Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
[TBL] [Abstract][Full Text] [Related]
18. Zinc as adjunct treatment in infants aged between 7 and 120 days with probable serious bacterial infection: a randomised, double-blind, placebo-controlled trial.
Bhatnagar S; Wadhwa N; Aneja S; Lodha R; Kabra SK; Natchu UC; Sommerfelt H; Dutta AK; Chandra J; Rath B; Sharma M; Sharma VK; Kumari M; Strand TA
Lancet; 2012 Jun; 379(9831):2072-8. PubMed ID: 22656335
[TBL] [Abstract][Full Text] [Related]
19. Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) randomised clinical trial: study protocol.
Daneman N; Rishu AH; Pinto RL; Arabi YM; Cook DJ; Hall R; McGuinness S; Muscedere J; Parke R; Reynolds S; Rogers B; Shehabi Y; Fowler RA;
BMJ Open; 2020 May; 10(5):e038300. PubMed ID: 32398341
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of adjunctive rifampicin for treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis of randomized controlled trials.
Dotel R; Gilbert GL; Hutabarat SN; Davis JS; O'Sullivan MVN
J Antimicrob Chemother; 2023 Oct; 78(10):2419-2427. PubMed ID: 37583062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
